Country Alternatives assessed Type of financial investigation Patient population studied Outcome Estimates Cost categories included Conclusions.
(2009) Australia - Voriconazole and LAmB, CEA, Hematology oncology patients predominantly with AML undergoing chemotherapy or HSCT. 5-point composite outcome measure, drug acquisition, routine costs, monitoring tests. LAmB net cost saving AU$1422 per patient treated.
(2009) Australia - Caspofungin and LAmB, CMA, Hematology oncology patients predominantly with AML undergoing chemotherapy or HSCT. 5-point composite outcome measure, drug acquisition, outlay costs, monitoring tests. Caspofungin net cost saving AU$7245 per patient treated.
(2012) Australia - Caspofungin and voriconazole, CMA, Hematology oncology patients predominantly with AML undergoing chemotherapy or HSCT. 5-point composite outcome measure, drug acquisition, outlay costs, monitoring tests. Caspofungin net cost saving AU$798 per patient treated.
(2007) UK - Caspofungin and LAmB, CUA, Hematology oncology patients predominantly with AML undergoing chemotherapy or HSCT. 5-point composite outcome measure and QALY. Drug acquisition, outlay costs, mild toxicity costs (e.g., chills, nausea). Caspofungin net cost saving GBP£2033 per patient treated, caspofungin 0.40 extra QALYs saved.
(2007) USA - Voriconazole and LAmB, CMA, Adult hematology patients receiving study drug post-chemotherapy for leukemia, lymphoma, or other hematological tumors. Retrospective chart review of response rates and adverse effects. Drug acquisition, nephrotoxicity treatment cost, routine costs. 27% reduced treatment cost with voriconazole (US$14950 vs US$20591).
(2008) Germany - Caspofungin and LAmB, CMA, Hematology oncology patients predominantly with AML undergoing chemotherapy or HSCT. NNT for harm from nephrotoxicity and reduced bed days. Staff costs, all medication costs, infrastructure, microbiology. 8.9 fewer patients (of 100 randomized) experienced worsening renal function. NNT for harm by LAmB of 12, 0.48 more bed days per patient treated with LAmB, €298 extra cost per patient treated with LAmB compared to caspofungin.
(2008) Italy - Caspofungin and LAmB, CUA, Hematology oncology patients predominantly with AML undergoing chemotherapy or HSCT. 5-point composite outcome measure and QALY. Drug acquisition, outlay costs, mild toxicity costs (e.g., chills, nausea). Caspofungin net cost saving €3470 per patient treated, caspofungin 0.25 extra QALYs saved.
(2007) USA - Caspofungin and LAmB, CMA, Hematology oncology patients predominantly with AML undergoing chemotherapy or HSCT. Rate of impaired renal function, drug acquisition, nephrotoxicity treatment costs. Overall treatment cost US$5326 less with caspofungin.
(2011) Sweden - Caspofungin and LAmB, CUA, Hematology oncology patients predominantly with AML undergoing chemotherapy or HSCT. 5-point composite outcome measure and QALY. Drug acquisition, routine costs, mild toxicity costs (e.g., chills, nausea). Caspofungin net cost saving SEK38,080, caspofungin 0.25 extra QALYs saved.
(2008) Spain - Voriconazole, caspofungin, LAmB, and amphotericin B Lipid complex, CEA, Onco-hematological patients at high risk of IFI receiving empiric antifungal treatment. Partial or complete response with or without adverse drug reactions. Drug acquisition, outlay costs, diagnostic tests, monitoring tests. Voriconazole favored with a €144,794 net cost saving compared to caspofungin as the next best alternative.
(2007) USA - Voriconazole and LAmB, CEA, Adult patients undergoing chemotherapy for leukemia, lymphoma, or other hematologic malignancies. Excluded standard fungal infections within 24h. 4-point composite outcome measure, drug acquisition, outlay costs. Voriconazole net cost saving of US$2551 per episode.
No comments:
Post a Comment